Literature DB >> 26430233

Juvenile fibromyalgia in an adolescent patient with sickle cell disease presenting with chronic pain.

Stalin Ramprakash1, Daniel Fishman2.   

Abstract

Juvenile fibromyalgia in children with sickle cell disease has not been reported in the literature. We report an adolescent patient with sickle cell whose pain symptoms progressed from having recurrent acute sickle cell pain crisis episodes to a chronic pain syndrome over several years. He was eventually diagnosed with juvenile fibromyalgia based on the clinical history and myofascial tender points and his pain symptoms responded better to multidisciplinary strategies for chronic fibromyalgia pain. Chronic pain in sickle cell disease is an area of poor research, and in addition there is inconsistency in the definition of chronic pain in sickle cell disease. Central sensitisation to pain is shown to occur after recurrent painful stimuli in a genetically vulnerable individual. In a chronic pain condition such as fibromyalgia central sensitisation is thought to play a key role. Fibromyalgia should be considered as one of the main differential diagnosis in any sickle cell patient with chronic pain. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26430233      PMCID: PMC4600816          DOI: 10.1136/bcr-2015-211850

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  32 in total

1.  Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits.

Authors:  Hagit Cohen; Dan Buskila; Lily Neumann; Richard P Ebstein
Journal:  Arthritis Rheum       Date:  2002-03

2.  Treatment of children with unexplained chronic pain.

Authors:  Susmita Kashikar-Zuck
Journal:  Lancet       Date:  2006-02-04       Impact factor: 79.321

3.  Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up.

Authors:  D M Siegel; D Janeway; J Baum
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

4.  Fibromyalgia and chronic fatigue syndrome in children.

Authors:  Yasuhiko Itoh; Tomoko Shigemori; Tohru Igarashi; Yoshitaka Fukunaga
Journal:  Pediatr Int       Date:  2012-01-12       Impact factor: 1.524

5.  The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations.

Authors:  Amanda M Brandow; Steven J Weisman; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2010-12-15       Impact factor: 3.167

6.  Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.

Authors:  Savaş Gürsoy; Emin Erdal; Hasan Herken; Ercan Madenci; Belgin Alaşehirli; Nurten Erdal
Journal:  Rheumatol Int       Date:  2002-10-22       Impact factor: 2.631

7.  Genetic linkage analysis of multicase families with fibromyalgia syndrome.

Authors:  M B Yunus; M A Khan; K K Rawlings; J R Green; J M Olson; S Shah
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  ISSLS prize winner: early predictors of chronic work disability: a prospective, population-based study of workers with back injuries.

Authors:  Judith A Turner; Gary Franklin; Deborah Fulton-Kehoe; Lianne Sheppard; Bert Stover; Rae Wu; Jeremy V Gluck; Thomas M Wickizer
Journal:  Spine (Phila Pa 1976)       Date:  2008-12-01       Impact factor: 3.468

Review 9.  Pediatric fibromyalgia.

Authors:  Dan Buskila
Journal:  Rheum Dis Clin North Am       Date:  2009-05       Impact factor: 2.670

Review 10.  Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews.

Authors:  Kurt Kroenke; Erin E Krebs; Matthew J Bair
Journal:  Gen Hosp Psychiatry       Date:  2009-03-04       Impact factor: 3.238

View more
  1 in total

1.  Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.

Authors:  Amanda M Brandow; Nancy J Wandersee; Mahua Dasgupta; Raymond G Hoffmann; Cheryl A Hillery; Cheryl L Stucky; Julie A Panepinto
Journal:  Br J Haematol       Date:  2016-08-19       Impact factor: 6.998

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.